News Center

Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China

12月 21, 2017 | 未分类
Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China Tracon - Ambrx PR, Final (12.21.17) - CN...

Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

4月 25, 2017 | 未分类
Primary endpoint of significant reduction in liver fat achieved following 16 weeks of treatment with...

Ambrx closes $45M round of financing

8月 4, 2016 | 未分类
SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates, today announced that...

Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients

3月 21, 2016 | 未分类
SAN DIEGO, March 21, 2016 - Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) announced today that they initiated First-In-Human phase I clinical trial with ARX788, Ambrx's most advanced internally developed site-specific...

Ambrx Announces New Chief Medical Officer

11月 16, 2015 | 未分类
SAN DIEGO, Nov. 16, 2015  Ambrx today announced the appointment of Yong-Jiang Hei, M.D., Ph.D. as Chief Medical Officer (CMO) reporting directly to CEO, Tiecheng "Alex" Qiao. With nearly...